Want to see SMMT full AI Analyst Report?
SMMT Stock Chart & Stats
$14.23
-$0.55(-4.06%)
At close: 4:00 PM EDT
$14.23
-$0.55(-4.06%)
Day’s Range― - ―
52-Week Range$12.07 - $29.23
Previous Close$13.23
Volume4.23M
Average Volume (3M)5.95M
Market Cap
$13.08B
Enterprise Value$10.67K
Total Cash (Recent Filing)$690.68M
Total Debt (Recent Filing)$20.38M
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Nov 11, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding797,749,600
10 Day Avg. Volume6,037,226
30 Day Avg. Volume5,950,851
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)26.74
Price to Sales (P/S)0.00
P/FCF Ratio-54.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.26Price Target Upside98.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)-1.17
Revenue Forecast (FY)$3.66M
Bulls Say, Bears Say
Bulls Say
Positive Phase III Efficacy Across Multiple Cancer StudiesConsistent efficacy across multiple Phase III studies and tumor settings strengthens ivonescimab’s potential differentiation in oncology. Repeated survival benefits and no new safety signals support broader development, partner interest, and the possibility of durable commercial relevance if regulatory milestones are achieved.
Strategic AstraZeneca Partnership Expands Funding And Oncology OpportunitiesA major-pharma investment provides external validation of ivonescimab and strengthens Summit’s resources for late-stage development. Shared-cost combination studies also broaden the potential treatment landscape and deepen strategic relationships that may improve Summit’s position in next-generation immuno-oncology.
Broad Global Clinical Footprint And Established Patient ExposureThe extensive clinical footprint gives Summit substantial evidence generation across indications, geographies, and combinations. Commercial patient exposure in China adds real-world experience, while the large Phase III pipeline creates multiple potential approval and expansion paths beyond the initial lung-cancer opportunity.
Bears Say
Pre-revenue Model And Substantial Ongoing LossesWithout meaningful product revenue, Summit’s financial performance remains dependent on collaboration income, financing, and future clinical success rather than an established commercial base. Large losses reduce earnings visibility and make the company’s durable financial profile highly sensitive to development outcomes.
High And Rising Cash Burn From Global Phase III DevelopmentHeavy operating cash use and rising clinical expenses reflect the cost of advancing several global Phase III programs simultaneously. Continued spending at this scale can shorten the period before additional capital is required, increasing financial pressure even while the pipeline advances.
Regulatory And Statistical Hurdles Could Delay CommercializationApproval depends on meeting a specific overall-survival standard, and the company has not yet received FDA feedback on submitted updated data. Multiple interim analyses, differing regional maturity, and slower event rates could complicate interpretation or extend the path to commercialization.
Summit Therapeutics News
SMMT FAQ
What was Summit Therapeutics’s price range in the past 12 months?
Summit Therapeutics lowest stock price was $12.07 and its highest was $29.23 in the past 12 months.
What is Summit Therapeutics’s market cap?
Summit Therapeutics’s market cap is $13.08B.
When is Summit Therapeutics’s upcoming earnings report date?
Summit Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 41 days.
How were Summit Therapeutics’s earnings last quarter?
Summit Therapeutics released its earnings results on Jul 23, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.274 by -$0.006.
Is Summit Therapeutics overvalued?
According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued.
Does Summit Therapeutics pay dividends?
Summit Therapeutics does not currently pay dividends.
What is Summit Therapeutics’s EPS estimate?
Summit Therapeutics’s EPS estimate is -0.29.
How many shares outstanding does Summit Therapeutics have?
Summit Therapeutics has 797,749,600 shares outstanding.
What happened to Summit Therapeutics’s price movement after its last earnings report?
Summit Therapeutics reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.274. Following the earnings report the stock price went down -8.812%.
Which hedge fund is a major shareholder of Summit Therapeutics?
Currently, no hedge funds are holding shares in SMMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Summit Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.26 (98.62% Upside)
$28.26 (98.62% Upside)
Blogger Sentiment
Bullish
SMMT Sentiment 90%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 3.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 11.4%
Last 30 Days ▲ 18.8%
Last 30 Days ▲ 18.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
132.13%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Summit Therapeutics
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
SMMT Company Deck
SMMT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical progress for ivonescimab — multiple positive Phase III PFS readouts, overall survival hazard ratios consistently under 0.80, extensive global clinical activity, commercial exposure in China, and a strong cash balance with no debt. Key near-term catalysts include the FDA PDUFA date (Nov 14, 2026) and upcoming HARMONi-3 interim analyses. Offsetting risks include accelerating operating costs and cash burn, reliance on ATM financings, regulatory uncertainty around statistically significant OS for approval, and the statistical/operational complexity introduced by multiple interim OS looks and regional maturity differences. Overall, the positives around clinical data and pipeline breadth outweigh the financial and regulatory risks presented on the call.View all SMMT earnings summariesSMMT Stock 12 Month Forecast
Average Price Target
$28.26
▲(98.62% Upside)